- Home
- NAUT vs STTK Comparison
NAUT vs STTK Comparison
Compare NAUT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- STTK
- Stock Information
- Founded
- NAUT 2016
- STTK 2016
- Country
- NAUT United States
- STTK United States
- Employees
- NAUT N/A
- STTK N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- STTK Health Care
- Exchange
- NAUT Nasdaq
- STTK Nasdaq
- Market Cap
- NAUT 104.7M
- STTK 112.6M
- IPO Year
- NAUT N/A
- STTK 2020
- Fundamental
- Price
- NAUT $1.82
- STTK $1.91
- Analyst Decision
- NAUT Strong Sell
- STTK Hold
- Analyst Count
- NAUT 1
- STTK 5
- Target Price
- NAUT $1.75
- STTK $3.00
- AVG Volume (30 Days)
- NAUT 790.4K
- STTK 135.4K
- Earning Date
- NAUT 10-28-2025
- STTK 11-06-2025
- Dividend Yield
- NAUT N/A
- STTK N/A
- EPS Growth
- NAUT N/A
- STTK N/A
- EPS
- NAUT N/A
- STTK N/A
- Revenue
- NAUT N/A
- STTK $1,000,000.00
- Revenue This Year
- NAUT N/A
- STTK N/A
- Revenue Next Year
- NAUT N/A
- STTK N/A
- P/E Ratio
- NAUT N/A
- STTK N/A
- Revenue Growth
- NAUT N/A
- STTK N/A
- 52 Week Low
- NAUT $0.62
- STTK $0.69
- 52 Week High
- NAUT $2.51
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- NAUT 64.84
- STTK 47.96
- Support Level
- NAUT $1.60
- STTK $1.86
- Resistance Level
- NAUT $1.91
- STTK $2.06
- Average True Range (ATR)
- NAUT 0.21
- STTK 0.15
- MACD
- NAUT 0.02
- STTK -0.01
- Stochastic Oscillator
- NAUT 84.13
- STTK 53.52
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.